XML 29 R12.htm IDEA: XBRL DOCUMENT

Long-Term Investments

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Long Term Investment [Abstract]

LONG-TERM INVESTMENTS

6. LONG-TERM INVESTMENTS

(1)

The ownership percentages of each investee are listed as follows:

	Ownership percentage
	March 31,			December 31,			Accounting
Name of related party	2022			2021			treatments
Braingenesis Biotechnology Co., Ltd.		0.17	%		0.17	%	Cost Method
Genepharm Biotech Corporation		0.70	%		0.70	%	Cost Method
BioHopeKing Corporation		5.90	%		5.90	%	Cost Method
BioFirst Corporation		15.99	%		15.99	%	Equity Method
Rgene Corporation		31.62	%		31.62	%	Equity Method

(2)

The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Collaborating with the Company to develop and commercialize drugs
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

(3)

Long-term investment mainly consists of the following:

	March 31, 2022		December 31, 2021
	(Unaudited)
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.	$	7,698	$	7,941
Genepharm Biotech Corporation		23,503		24,244
BioHopeKing Corporation		873,053		900,570
Sub total		904,254		932,755
Equity Method Investments, net
BioFirst Corporation		-		-
Rgene Corporation		-		-
Total	$	904,254	$	932,755

(a)

BioFirst Corporation (the “BioFirst”):

The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December 31, 2021, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $663,798 and $684,720, recorded as prepayment for long-term investments as of March 31, 2022 and December 31, 2021, respectively.

Summarized financial information for the Company’s equity method investee, BioFirst, is as follows:

Balance Sheet

	March 31, 2022			December 31, 2021
	(Unaudited)
Current Assets	$	2,147,097		$	2,205,669
Non-current Assets		812,865			959,454
Current Liabilities		3,237,623			2,909,703
Non-current Liabilities		17,741			32,522
Stockholders’ Equity		(295,402	)		222,898

Statement of Operations

	Three Months Ended March 31,
	2022			2021
	(Unaudited)
Net sales	$	8,808		$	12,339
Gross profit		6,133			7,080
Net loss		(498,940	)		(220,855	)
Share of losses from investments accounted for using the equity method		-			(47,791	)

(b)

Rgene Corporation (the “Rgene”)

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December 31, 2021, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.

Summarized financial information for the Company’s equity method investee, Rgene, is as follows:

Balance Sheets

	March 31, 2022			December 31, 2021
	(Unaudited)
Current Assets	$	221,169		$	73,452
Noncurrent Assets		355,420			374,423
Current Liabilities		2,164,077			1,934,786
Noncurrent Liabilities		-			-
Shareholders’ Deficit		(1,587,488	)		(1,486,911	)

Statement of Operations

	Three Months Ended March 31,
	2022			2021
	(Unaudited)
Net sales	$	-		$	-
Gross Profit		-			-
Net loss		(149,480	)		(95,395	)
Share of loss from investments accounted for using the equity method		-			-

(4)

Disposition of long-term investment

During the three months ended March 31, 2022 and 2021, there is no disposition of long-term investment.

(5)

Losses on Equity Investments

The components of losses on equity investments for each period were as follows:

	Three Months Ended March 31,
	2022		2021
	(Unaudited)
Share of equity method investee losses	$	-	$	(47,791	)

6. LONG-TERM INVESTMENTS

(1)	The ownership percentages of each investee are listed as follows:

	Ownership percentage
	December 31,	December 31,	Accounting
Name of related party	2021	2020	treatments
Braingenesis Biotechnology Co., Ltd.	0.17%	0.17%	Cost Method
Genepharm Biotech Corporation	0.70%	0.70%	Cost Method
BioHopeKing Corporation	5.90%	5.90%	Cost Method
BioFirst Corporation	15.99%	15.99%	Equity Method
Rgene Corporation	31.62%	31.62%	Equity Method

(2)	The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from the investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

(3)	Long-term investment mainly consists of the following:

	December 31, 2021		December 31, 2020
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.	$	7,941	$	7,853
Genepharm Biotech Corporation		24,244		23,974
BioHopeKing Corporation		900,570		890,564
Sub total		932,755		922,391
Equity Method Investments, net
BioFirst Corporation		-		268,336
Rgene Corporation		-		-
Total	$	932,755	$	1,190,727

(a)	BioFirst Corporation (the “BioFirst”):

The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During year ended December 31, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $684,720, recorded as prepayment for long-term investments as of December 31, 2021.

Summarized financial information for the Company’s equity method investee, BioFirst, is as follows:

Balance Sheet

	December 31, 2021		December 31, 2020
Current Assets	$	2,205,669	$	1,299,822
Noncurrent Assets		959,454		2,540,041
Current Liabilities		2,909,703		1,986,340
Noncurrent Liabilities		32,522		73,197
Stockholders’ Equity		222,898		1,780,326

Statement of operation

	Year Ended December 31,
	2021			2020
Net sales	$	26,693		$	257,235
Gross profit		8,348			10,121
Net loss		(2,276,892	)		(5,401,074	)
Share of losses from investments accounted for using the equity method		(269,844	)		(1,168,733	)

(b)	Rgene Corporation (the “Rgene”)

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 31.62% and 31.62% common stock shares of Rgene, respectively.

Summarized financial information for the Company’s equity method investee, Rgene, is as follows:

Balance Sheets

	December 31, 2021			December 31, 2020
Current Assets	$	73,452		$	123,958
Noncurrent Assets		374,423			412,342
Current Liabilities		1,934,786			1,392,756
Noncurrent Liabilities		-			38,953
Shareholders’ Deficit		(1,486,911	)		(895,409	)

Statement of operations

	Year Ended December 31,
	2021			2020
Net sales	$	-		$	16,595
Gross Profit		-			(335,735	)
Net loss		(576,514	)		(641,636	)
Share of loss from investments accounted for using the equity method		-			-

(4)	Disposition of long-term investment

During the year ended December 31, 2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020. During the year ended December 31, 2021, there is no disposition of long-term investment.

(5)	Losses on Equity Investments

The components of losses on equity investments for each period were as follows:

	Year Ended December 31,
	2021			2020
Share of equity method investee losses	$	(269,844	)	$	(1,168,733	)